Pharmacological targeting of the cancer epigenome

NW Mabe, JA Perry, CF Malone, K Stegmaier - Nature Cancer, 2024 - nature.com
Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Biology of GD2 ganglioside: implications for cancer immunotherapy

P Machy, E Mortier, S Birklé - Frontiers in pharmacology, 2023 - frontiersin.org
Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide
bound to a sialic acid-containing glycan chain, and locate at the plasma membrane …

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK. CAR-T cells

E Bergaggio, WT Tai, A Aroldi, C Mecca, E Landoni… - Cancer Cell, 2023 - cell.com
Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen
receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic …

GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

R Ciccone, C Quintarelli, A Camera… - Clinical Cancer …, 2024 - aacrjournals.org
Abstract Purpose: Medulloblastoma (MB), the most common childhood malignant brain
tumor, has a poor prognosis in about 30% of patients. The current standard of care, which …

Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers

L Fischer-Riepe, S Kailayangiri… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Cytokine-engineering of chimeric antigen receptor-redirected T cells (CAR T cells)
is a promising principle to overcome the limited activity of canonical CAR T cells against …

Aberrant glycosylation as immune therapeutic targets for solid tumors

Y Matsumoto, T Ju - Cancers, 2023 - mdpi.com
Simple Summary Glycosylation is one of the most pivotal post-translational modifications on
all types of biomolecules for the formation of glycoproteins, glycolipids, and glycoRNAs in a …

Current and emerging biomarkers: Impact on risk stratification for neuroblastoma

MS Irwin, KC Goldsmith - Journal of the National Comprehensive Cancer …, 2024 - jnccn.org
Neuroblastoma has heterogenous clinical presentations that are reflected by several well-
defined clinical factors and biomarkers. Combinations of these clinical and biologic …

A developmental biliary lineage program cooperates with Wnt activation to promote cell proliferation in hepatoblastoma

PV Wu, M Fish, FK Hazard, C Zhu, S Vennam… - Nature …, 2024 - nature.com
Cancers evolve not only through the acquisition and clonal transmission of somatic
mutations but also by epigenetic mechanisms that modify cell phenotype. Here, we use …

Bioactive sphingolipids as emerging targets for signal transduction in cancer development

W Jia, J Yuan, J Zhang, S Li, W Lin, B Cheng - Biochimica et Biophysica …, 2024 - Elsevier
Sphingolipids, crucial components of cellular membranes, play a vital role in maintaining
cellular structure and signaling integrity. Disruptions in sphingolipid metabolism are …

[HTML][HTML] Targeting EZH2 in neuroblastoma

J Gao, C Fosbrook, J Gibson, TJ Underwood… - Cancer Treatment …, 2023 - Elsevier
Neuroblastoma is one of the commonest extra-cranial pediatric tumors, and accounts for
over 15% of all childhood cancer mortality. Risk stratification for children with neuroblastoma …